Eagle Pharmaceuticals, Inc. — Net Income by Fiscal Year
11 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/632a6891-8651-4162-964b-06beb5d728fd/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $35.6M | 2022-01-01 – 2022-12-31 | evidence 0000827871-23-000009 |
| FY 2021 | $-8.6M | 2021-01-01 – 2021-12-31 | evidence 0000827871-22-000008 |
| FY 2020 | $12.0M | 2020-01-01 – 2020-12-31 | evidence 0000827871-21-000011 |
| FY 2019 | $14.3M | 2019-01-01 – 2019-12-31 | evidence 0000827871-20-000007 |
| FY 2018 | $31.9M | 2018-01-01 – 2018-12-31 | evidence 0000827871-19-000008 |
| FY 2017 | $51.9M | 2017-01-01 – 2017-12-31 | evidence 0000827871-18-000003 |
| FY 2016 | $81.5M | 2016-01-01 – 2016-12-31 | evidence 0000827871-17-000002 |
| FY 2015 | $2.6M | 2015-01-01 – 2015-12-31 | evidence 0000827871-16-000049 |
| FY 2014 | $-18.0M | 2013-10-01 – 2014-09-30 | evidence 0000827871-14-000015 |
| FY 2013 | $-6.0M | 2012-10-01 – 2013-09-30 | evidence 0000827871-14-000015 |
| FY 2012 | $-19.4M | 2011-10-01 – 2012-09-30 | evidence 0000827871-14-000015 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Eagle Pharmaceuticals, Inc. — all facts · Revenue · Operating Income